Sydney, Australia 31 October 2017 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Professor Richard Wahl has joined their scientific advisory group. Richard Wahl, M.D., is the Elizabeth Mallinckrodt Professor, Chairman of the Department of Radiology and Director of the Mallinckrodt Institute of Radiology at Washington University School of Medicine in St Louis.
Prof Wahl is a world leader in the field of targeted radiopharmaceuticals for diagnosing and treating cancer. With an emphasis on positron emission tomography (PET) and multi-modality imaging, such as PET-CT, his work enabled precision diagnosis of a broad array of human cancers and other serious diseases. Prof Wahl is one of the inventors of radio-immunotherapy of lymphoma, which is a combination of radiotherapy and immunotherapy that facilitates targeted treatments. He has also been an inventor of a number of FDA approved medical devices, such as radionuclide guided biopsy. Prof Wahl and his research group have received research support from the National Institutes of Health (NIH) and other agencies for over three decades.
Before being named the Elizabeth E. Mallinckrodt Professor at Washington University School of Medicine in St. Louis in 2014, Prof Wahl was Professor of Radiology and Oncology, as well as the Henry N. Wagner Jr. Professor of Nuclear Medicine, at Johns Hopkins University. He was also Director of Nuclear Medicine, PET and the Vice Chair for Technology and Business Development. Prof Wahl received his MD degree at Washington University in St. Louis and after his residency there served as medical intern at the University of California at San Diego School of Medicine. He had fellowship training in Radiology and Nuclear Medicine at the Mallinckrodt Institute of Radiology and immunology training in the Howard Hughes Immunology Laboratories at Washington University.
Prof Wahl holds 18 radiology patents and has published more than 400 peer-reviewed scientific papers and several books. He is a member of a number of professional societies, including Radiological Society of North America (RSNA), where he is playing a leadership role in the Quantitative Imaging Biomarker Alliance Project, designed to standardise imaging approaches. He has received a variety of professional honours and has given multiple named lectureships including The New Horizons Lecture at the RSNA, the Marie Curie Lecture at the European Association of Nuclear Medicine (EANM), and the Henry Wagner lecture at the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Prof Wahl’s awards include a U.S. Department of Energy Achievement Award, the Berson-Yalow and Tetalman award and two Alavi-Mandel awards from the SNMMI, the Hounsfield Award from the Society of Body CT and MRI, the Distinguished Scientist Award from the Academy of Molecular Imaging (AMI) and the “Most Influential Radiology Researcher” from Aunt Minnie, a leading website for medical imaging professionals. He has served as a chairman of the American Board of Nuclear Medicine (ABNM), president of the Institute for Clinical PET (ICP), program and refresher course chair for RSNA, on multiple NIH and other study sections. He was elected as a member of the U.S. National Academy of Medicine in 2015.
Prof Wahl commented on his appointment “Clarity has made a significant contribution to the development and use of copper radio isotopes for diagnosis and therapy of cancer and other serious diseases. I am very excited about the potential of copper to answer a number of the limitations of radiopharmaceuticals today. I also believe that, through separate arrangements, Washington University in St. Louis is well placed to position itself as a key area of research, clinical trials and manufacturing for copper based products. I am eager to advise the Company, in my personal capacity as a consultant, on the development of its pipeline and application of their technology to new indications.”
Clarity’s Executive Chairman, Dr Alan Taylor said “Richard is a world leader in the radiopharmaceuticals space and we are very excited to have someone of his calibre joining our scientific advisory board. Not only his experience in clinical trials and product development will be invaluable to Clarity, his central location in St Louis will allow us to explore and implement a broader manufacturing and clinical trials site to industrialise our technology in the US. We are committed to working together to advance Clarity’s pipeline in order to provide better diagnostic and therapeutic solutions for oncology patients around the world.”
About Clarity
Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally.
www.claritypharmaceuticals.com
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
